HeyJaredJonathan Gardner
- Indexed articles, last 90 days
- 9
- Latest publication
- Oct 1, 2026
- Outlet visibility, for healthcaredive.com
- Top 1M sites
- Earliest in this view
- Jul 30, 2026
Latest articles
3 takeaways from a European obesity scientific meeting (opens the original)
Read excerpt
Eli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral. Obesity and metabolic disease specialists are gathering in Milan this week for the annual meeting of the European Association for the Study of Diabetes, one of a few opportunities for drugmakers developing weight-loss treatments to pitch data from experimental drugs to potential future prescribers. As expected, obesity leaders Eli Lilly and Novo made headl
Bristol Myers trial revisions shake confidence in new class of fibrosis drugs (opens the original)
Read excerpt
A spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of admilparant — though it’s unclear whether the drug was to blame. LPA1R inhibitors have already had a difficult time in clinical research. Bristol Myers Squibb canceled work on an earlier drug because of liver toxicity. Amgen shelved another it had inherited in a buyout of Horizon Therapeutics. Bristol Myers submitted the amendment to its trial practices for Euro
Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill (opens the original)
Read excerpt
The deal, which hands Novo a challenger to Lilly’s market-leading Zepbound, comes as the Danish drugmaker looks to calm investor fears about its future. Novo has spent the past year or so trying to reclaim ground it lost to Lilly. That strategy has included installing a new CEO and set of boardmembers, laying off thousands of workers and signing a series of deals to acquire next-generation weight loss medicines. In obesity, Novo and Lilly have established that GLP-1-targeting drugs can stimulate
BioMarin acquires experimental drug for rare bone disorder in $275M deal (opens the original)
Read excerpt
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. BioMarin Pharmaceutical is boosting its pipeline of experimental drugs for skeletal and muscle diseases, announcing Tuesday the acquisition of privately held Alesta Therapeutics and its therapy for a rare bone-wasting disease. Per deal terms, BioMarin will pay $275 million up front and potentially as much as $215 million more based on the achievement o
Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs (opens the original)
Read excerpt
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The CEO who helped guide development of the top-selling cell therapy for multiple myeloma will take the reins of a young startup searching the world for new drug prospects. On Tuesday, that startup, K2 Therapeutics, announced that former Legend Biotech CEO Ying Huang has been named its new leader. It's also secured $50 million in seed financing to supp
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1M sites
For healthcaredive.com, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.